390 Emerging safety and activity data from GEN-009–101: A phase 1/2a trial of GEN-009, a neoantigen vaccine in combination with PD-1 check-point inhibitors (CPI) in advanced solid tumors

390 Emerging safety and activity data from GEN-009–101: A phase 1/2a trial of GEN-009, a neoantigen vaccine in combination with PD-1 check-point inhibitors (CPI) in advanced solid tumors

Bibliographic Details
Main Authors: Thomas Davis, Jessica Price, Ammar Sukari, Roger Cohen, Przemyslaw Twardowski, Jessica Flechtner, Melissa Johnson, Maura Gillison, Rudy Lackner, Arthur DeCillis, Richard Hernandez, Kevin Mancini, Mara Shainheit
Format: Article
Language:English
Published: BMJ Publishing Group 2020-11-01
Series:Journal for ImmunoTherapy of Cancer
id doaj-26d2fd7d8bed4b769e10d720e04ce8c6
record_format Article
spelling doaj-26d2fd7d8bed4b769e10d720e04ce8c62020-12-11T10:01:50ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262020-11-018Suppl 310.1136/jitc-2020-SITC2020.0390390 Emerging safety and activity data from GEN-009–101: A phase 1/2a trial of GEN-009, a neoantigen vaccine in combination with PD-1 check-point inhibitors (CPI) in advanced solid tumorsThomas Davis0Jessica Price1Ammar Sukari2Roger Cohen3Przemyslaw Twardowski4Jessica Flechtner5Melissa Johnson6Maura Gillison7Rudy Lackner8Arthur DeCillis9Richard Hernandez10Kevin Mancini11Mara Shainheit127Genocea Biosciences, Centreville, MD, USAGOSHAff238 grid.254444.70000000114567807Karmanos Cancer Institute Detroit MI USA Aff452 grid.25879.310000000419368972University of Pennsylvania Philadelphia PA USA Aff5 grid.410425.60000000404218357City of Hope Duarte CA USA Aff1 grid.475330.60000000405579162Genocea Biosciences, Inc Cambridge MA USA 3Sarah Cannon Research Institute, Nashville, TN, USA2MD Anderson Cancer Center, Houston, TX, USA6University of Nebraska, Omaha, NE, USA7Genocea Biosciences, Centreville, MD, USA7Genocea Biosciences, Centreville, MD, USA7Genocea Biosciences, Centreville, MD, USA7Genocea Biosciences, Centreville, MD, USA
collection DOAJ
language English
format Article
sources DOAJ
author Thomas Davis
Jessica Price
Ammar Sukari
Roger Cohen
Przemyslaw Twardowski
Jessica Flechtner
Melissa Johnson
Maura Gillison
Rudy Lackner
Arthur DeCillis
Richard Hernandez
Kevin Mancini
Mara Shainheit
spellingShingle Thomas Davis
Jessica Price
Ammar Sukari
Roger Cohen
Przemyslaw Twardowski
Jessica Flechtner
Melissa Johnson
Maura Gillison
Rudy Lackner
Arthur DeCillis
Richard Hernandez
Kevin Mancini
Mara Shainheit
390 Emerging safety and activity data from GEN-009–101: A phase 1/2a trial of GEN-009, a neoantigen vaccine in combination with PD-1 check-point inhibitors (CPI) in advanced solid tumors
Journal for ImmunoTherapy of Cancer
author_facet Thomas Davis
Jessica Price
Ammar Sukari
Roger Cohen
Przemyslaw Twardowski
Jessica Flechtner
Melissa Johnson
Maura Gillison
Rudy Lackner
Arthur DeCillis
Richard Hernandez
Kevin Mancini
Mara Shainheit
author_sort Thomas Davis
title 390 Emerging safety and activity data from GEN-009–101: A phase 1/2a trial of GEN-009, a neoantigen vaccine in combination with PD-1 check-point inhibitors (CPI) in advanced solid tumors
title_short 390 Emerging safety and activity data from GEN-009–101: A phase 1/2a trial of GEN-009, a neoantigen vaccine in combination with PD-1 check-point inhibitors (CPI) in advanced solid tumors
title_full 390 Emerging safety and activity data from GEN-009–101: A phase 1/2a trial of GEN-009, a neoantigen vaccine in combination with PD-1 check-point inhibitors (CPI) in advanced solid tumors
title_fullStr 390 Emerging safety and activity data from GEN-009–101: A phase 1/2a trial of GEN-009, a neoantigen vaccine in combination with PD-1 check-point inhibitors (CPI) in advanced solid tumors
title_full_unstemmed 390 Emerging safety and activity data from GEN-009–101: A phase 1/2a trial of GEN-009, a neoantigen vaccine in combination with PD-1 check-point inhibitors (CPI) in advanced solid tumors
title_sort 390 emerging safety and activity data from gen-009–101: a phase 1/2a trial of gen-009, a neoantigen vaccine in combination with pd-1 check-point inhibitors (cpi) in advanced solid tumors
publisher BMJ Publishing Group
series Journal for ImmunoTherapy of Cancer
issn 2051-1426
publishDate 2020-11-01
work_keys_str_mv AT thomasdavis 390emergingsafetyandactivitydatafromgen009101aphase12atrialofgen009aneoantigenvaccineincombinationwithpd1checkpointinhibitorscpiinadvancedsolidtumors
AT jessicaprice 390emergingsafetyandactivitydatafromgen009101aphase12atrialofgen009aneoantigenvaccineincombinationwithpd1checkpointinhibitorscpiinadvancedsolidtumors
AT ammarsukari 390emergingsafetyandactivitydatafromgen009101aphase12atrialofgen009aneoantigenvaccineincombinationwithpd1checkpointinhibitorscpiinadvancedsolidtumors
AT rogercohen 390emergingsafetyandactivitydatafromgen009101aphase12atrialofgen009aneoantigenvaccineincombinationwithpd1checkpointinhibitorscpiinadvancedsolidtumors
AT przemyslawtwardowski 390emergingsafetyandactivitydatafromgen009101aphase12atrialofgen009aneoantigenvaccineincombinationwithpd1checkpointinhibitorscpiinadvancedsolidtumors
AT jessicaflechtner 390emergingsafetyandactivitydatafromgen009101aphase12atrialofgen009aneoantigenvaccineincombinationwithpd1checkpointinhibitorscpiinadvancedsolidtumors
AT melissajohnson 390emergingsafetyandactivitydatafromgen009101aphase12atrialofgen009aneoantigenvaccineincombinationwithpd1checkpointinhibitorscpiinadvancedsolidtumors
AT mauragillison 390emergingsafetyandactivitydatafromgen009101aphase12atrialofgen009aneoantigenvaccineincombinationwithpd1checkpointinhibitorscpiinadvancedsolidtumors
AT rudylackner 390emergingsafetyandactivitydatafromgen009101aphase12atrialofgen009aneoantigenvaccineincombinationwithpd1checkpointinhibitorscpiinadvancedsolidtumors
AT arthurdecillis 390emergingsafetyandactivitydatafromgen009101aphase12atrialofgen009aneoantigenvaccineincombinationwithpd1checkpointinhibitorscpiinadvancedsolidtumors
AT richardhernandez 390emergingsafetyandactivitydatafromgen009101aphase12atrialofgen009aneoantigenvaccineincombinationwithpd1checkpointinhibitorscpiinadvancedsolidtumors
AT kevinmancini 390emergingsafetyandactivitydatafromgen009101aphase12atrialofgen009aneoantigenvaccineincombinationwithpd1checkpointinhibitorscpiinadvancedsolidtumors
AT marashainheit 390emergingsafetyandactivitydatafromgen009101aphase12atrialofgen009aneoantigenvaccineincombinationwithpd1checkpointinhibitorscpiinadvancedsolidtumors
_version_ 1724386540832948224

Similar Items